ASC 2012 | Prof. Aaron Ciechanover | The Personalized Medicine Revolution
1,272 views · Published 27 August 2012 · 1:17:10 · Indexed 23 October 2026
Channel: Hebrew University of Jerusalem · 2012 · Education
Aaron Ciechanover Nobel Laureate -- Chemistry 2004 Cancer and Vascular Biology Research Center, Faculty of Medicine, Technion-Israel Institute of Technology The Personalized Medicine Revolution: Are We Going to Cure all Diseases and at what Price? Many important drugs such as penicillin, aspirin, or digitalis, were discovered by serendipity -- some by curious researchers who accidentally noted a "strange" phenomenon, and some by isolation of active ingredients form plants known for centuries to have a specific therapeutic effect. Other major drugs like the cholesterol reducing statins were discovered using more advanced technologies, such as targeted screening of large chemical libraries. In all these cases, the mechanism of action of the drug were largely unknown at the time of their discovery, and were unraveled only later. With the realization that patients with apparently similar diseases at diagnosis -- breast or prostate cancer, for example -- respond differently to similar treatments, and the clinical behavior of the disease is different in different patients, we have begun to understand that the mechanistic/molecular basis of what we thought is the same disease entity, is different Thus, breast cancer or prostate cancers appear to be sub-divided to smaller distinct classes according to their molecular characteristics. As a result, we are exiting the era where our approach to treatment of these and many other diseases is "one size fits all", and enter a new era of "personalized medicine" where we shall tailor the treatment according to the patient's molecular/mutational profile. Here, unlike the previous era, the understanding of the mechanism will drive the development of new drugs. This era will be characterized initially by the development of technologies where sequencing and data processing of individual genomes will be fast (few hours) and cheap by identification and characterization of new disease-specific molecular markers and drug targets, and by design of novel, mechanism-based drugs to modulate the activities of these targets. It will require a change in our approach to scientific research and development and to education, where interdisciplinarity will domineer and replace in many ways the traditional, discipline-oriented approach. Entry into this era will be also accompanied by complex bioethical problems, where detailed genetic information of large populations in developed countries will be available, and protection of privacy will become an important issue for health authorities.
More from this channel
-
1:22:14
פרופ' אברהם הוכברג- הגן H-19, תקווה חדשה לחולי סרטן
-
1:22:54
מר משה נגבי- על היעדר האחריותיות בדמוקרטיה הישראלית
-
1:30:58
פרופ' ששון צחייק- מדע הכימיה
-
1:13:59
פרופ' אבנר דה שליט- על מורשת, מקום ותכנון בר קיימא
-
1:17:03
פרופ' ארי לאור- עדויות לקיומם של חורים שחורים ענקיים
-
1:07:28
פרופ' ניר שביב- על קרינה קוסמית ואקלים כדור-הארץ
-
1:21:11
ד"ר דני צ'רנוב- השפעת שינויי האקלים על שונית האלמוגים
-
1:06:27
ד"ר ארז ריבק - חידוד הדמות בשמים ובעיניים